Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label olaparib in advanced BRCA1/2-mutated cancers
2010-022278-15Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in cancer and prostate cancer (PCa), sponsored by AstraZeneca. Primary endpoint: Tumor response. Started Sep 2010; status: completed.
02
Drugs
olaparib
03
Conditions
cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2010-022278-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022278-15.